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INTRODUCTION 
 
             Surgery and anaesthesia induce considerable emotional stress  
and  psychological consequences in children. This stress may remain in 
the child’s psyche long after the hospital experience has passed, and it 
was first described by Duputyren in 1834. 
Age, parental anxiety level, previous hospital experiences and 
type of surgery are factors that can influence a child’s anxiety level and 
psychological well being. 
 Preoperative anxiety stimulates sympathetic, parasympathetic and 
endocrine system leading to an increase in heart rate, blood pressure and 
cardiac excitability. These reactions reflect the child’s  
• fear of separation from parents and home environment  
• fear of physical harm 
• fear of unfamiliar routines 
• fear of  surgical instruments and procedures 
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 The preoperative interventions directed towards reduction of 
anxiety can be grouped into psychological and pharmacological 
methods. The introduction of new drugs and alternative routes of 
administration like transmucosal route in last decade by avoiding  
painful intramuscular  injections, the most horrifying experience for a 
child, has facilitated  a more rational approach to premedication for 
paediatric patients. 
 In paediatric anaesthesia, premedication needs to be in an 
acceptable form, to have a rapid onset with minimal hangover effect and 
without side effects. Midazolam, a sedative with all the desirable 
properties of a benzodiazepine was introduced into clinical practice in 
1980s. 
 Midazolam, a water soluble benzodiazepine, may be administered 
by various routes. Oral and rectal routes are used widely and provide 
effective sedation. However, there are concerns about the wide 
bioavailability when given by these routes , ranging from 18% to 44% 
with an appreciable first pass effect. Intramuscular administration is 
painful and the sublingual route has poor compliance.  
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 The intranasal route for midazolam has been used since 1988 and 
has the advantage of rapid absorption directly into the systemic 
circulation with no first pass effect and a bio- availability of 55-83%  
 Intranasal midazolam is absorbed from an area rich in blood 
supply and avoids the disadvantage of passing through the portal 
circulation, thus increasing the bio-availability of the drug.  Tolerance to 
midazolam is good, and the duration of action is shorter and more 
predictable than other benzodiazepines. Intranasal midazolam has all the 
advantages of intravenous administration without the disadvantages of 
pain and fear associated with   intramuscular and intravenous injections. 
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AIM OF THE STUDY 
 
 The aim of the study is to compare the effectiveness of Intranasal 
and oral midazolam used as a premedication in paediatric patients 
undergoing minor elective surgical procedures. 
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PREMEDICATION IN CHILDREN 
 
 Finding a suitable premedicant for children and the best route of 
administration  is something that has been investigated for a long time.  
 An ideal paediatric premedication should 
• allay anxiety and fear 
•  be easily available and affordable 
• produce the desired clinical effect 
• enable smooth separation from parents 
• abolish any preoperative pain 
• facilitate smooth induction 
• reduce the dose of anaesthetic 
• maintain vital functions 
• maintain airway reflexes 
• offer rapid postoperative recovery 
• easily acceptable by parents 
• have minimal hangover effect 
• should produce amnesia of transfer and  entry into the 
operating room 
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 The advantages and disadvantages of various routes of 
administration are as follows.  
Sl. 
No. 
Route of 
Administration Advantages Disadvantages 
1 Oral Painless 
Variable onset and 
depth of sedation, 
prolonged effect, 
Nausea 
2 Intramuscular 
Reliable, Rapid onset, 
better absorption,  
greater predictability  
of the duration of 
action 
Painful, threatening, 
risk of infection, 
abscess formation, 
required skilled 
personnel 
3 Rectal Reliable,  Rapid onset
Distressing procedure, 
defaecation, irregular 
absorption, first pass 
effect 
4 Intravenous 
Most Reliable, Rapid 
onset 
Painful,  threatening, 
risk of infection, 
requires skill 
5 Nasal 
Rapid, Reliable onset 
of action, No first pass 
effect, No risk of 
infection 
Objection, coughing, 
sneezing,  swallowing 
6 Sublingual  
Painless, No first pass 
effect, No  risk of 
infection 
Nausea and vomiting,  
slower onset 
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Transmucosal routes 
 Drug absorption through a mucosal surface is generally efficient 
because mucosal surfaces are usually rich in blood supply, providing the 
means for rapid drug transport to the systemic circulation and avoiding 
degradation by first-pass hepatic metabolism. 
 The amount of drug absorbed depends on the following factors 
• drug concentration 
• vehicle of drug delivery 
• mucosal contact time 
• venous drainage of the mucosal tissues 
• degree of the drug ionization and  
• pH of  the absorption site 
• size of the drug molecule 
• relative lipid solubility 
 Distribution of the drug depends on the following factors 
• Formulation 
• Dilution 
• Particle size 
• Lipid solubility 
• Site of administration 
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MIDAZOLAM PHARMACOLOGY  
 
 Midazolam is a short-acting, water soluble benzodiazepine and 
central nervous system depressant that was introduced into clinical 
practice in 1980s. It is two to three times as potent as diazepam. 
Structure 
 Chemically Midazolam is composed of a benzene ring  fused to a 
7 membered benzodiazepine ring. It has a molecular formula of 
C18H13Cl FN3  and a calculated molecular weight of 325.8                 
 Midazolam is 8-chloro-6-(2-flourophenyl)-1-methyl- 4H-imidazo 
(1,5-a) (1,4) benzodiazepine. 
Ring Opening Phenomenon 
 The pK of  midazolam is  6.15,  which permits the preparation of  
salts that are water soluble. The parenteral solution of midazolam used 
clinically is buffered to an acidic pH of 3.5 . This is important because 
midazolam is characterized by a pH dependent Ring Opening 
phenomenon in which the ring remains open at pH values of < 4, thus 
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maintaining water solubility of the drug. The ring closes at pH values of >4, 
as when the drug is exposed to physiologic pH, thus converting 
midazolam to a highly lipid soluble drug.  The imidazole ring in its 
structure accounts for stability in aqueous solutions and rapid 
metabolism. 
Pharmacodynamics 
 Midazolam has the following six principal pharmacological 
actions. 
• Anxiolysis 
• Sedation 
• Anticonvulsant 
• Skeletal muscle relaxation 
• Anterograde amnesia 
• Hypnosis 
 The pharmacological effects of midazolam   results from 
reversible interactions with the Gamma-Amino Butyric Acid (GABA) 
benzodiazepine receptor, the major inhibitory neurotransmitter in the 
central nervous system. 
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Pharmacokinetics 
 Midazolam  undergoes rapid absorption from the gastrointestinal 
tract and prompt passage across the Blood Brain Barrier. 
 Absorption of midazolam is rapid, peak plasma concentrations 
being achieved within 20 to 60  minutes of administration depending on 
the route.  Only about 50% of an orally administered dose of midazolam 
reaches the systemic circulation, reflecting a substantial first-pass 
hepatic effect. 
  Midazolam is extensively bound to plasma proteins. (96-98%). 
This binding is independent of the plasma concentration of midazolam. 
 The elimination half time of midazolam is 1- 4 hours, which is 
much shorter than that of diazepam. The short duration of action of 
midazolam is due to its lipid solubility, leading to rapid redistribution 
from the brain to inactive tissues and rapid hepatic clearance. 
 The volume of  distribution (Vd) of midazolam is 1.0-1.5 l/ kg. 
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Metabolism 
 Midazolam is rapidly metabolized by hepatic and small intestine 
cytochrome p-450 (CYP3A4) enzymes to active and inactive 
metabolites . 
 The principal metabolite of midazolam, 1–hydroxy midazolam 
has approximately half the activity of the parent compound. This active 
metabolite is rapidly conjugated to 1-hydroxy midazolam glucuronide 
and is subsequently cleared by the kidneys. The other pharmacologically 
active metabolites like 4 hydroxy midazolam is not present in detecteble 
concentratoions in the plasma. 
 Metabolism of midazolam is slowed in the presence of drugs such 
as Cimetidine, Erythromycin, Calcium channel blockers, antifungal 
drugs that inhibit  cytochrome p-450 enzymes resulting in unexpected 
CNS depression. 
 Hepatic clearance rate of midazolam is 5 times greater than that of 
lorazepam and 10 times greater than that of diazepam. 
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Clinical uses 
• Prepoperative medication 
• Conscious sedation 
• Induction of maintenance 
• Maintenance of anaesthesia 
• Postoperative sedation 
• Grandmal seizures 
• Febrile seizures  
 13
 
ANATOMY AND PHYSIOLOGY OF THE  
NASAL MUCOSA 
 
 Although, phylogenetically, the olfactory function of the nose is  
of major importance, physiologically the  nasal structure and function in 
humans relate primarily to humidification, warming and filtration of 
inspired air. The nose is richly vascularised with numerous  microvilli 
and a relatively large surface area  for these functions. The nasal cavity 
and septum are lined by simple ciliated columnar epithelium. 
 The subepithelial capillaries are lined with fenestrated  
endothelium, which possesses porous  basement membrane. It appears 
that nasal vascular bed is designed for the passage of fluids and 
dissolved substances from the blood vessels to tissues and vice versa. 
This property of nasal mucosa is favourable  for intranasal drug  
administration. Moreover, drugs absorbed through the nasal vasculature  
avoids the first pass effects through the liver and degradation in the 
luminal  fluids of the  gastrointestinal tract . 
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Nasal muosal administration 
 Nasal mucosa is the only location in the body that provides a 
direct connection between the central nervous system and the 
atmosphere. Drugs sprayed into the olfactory mucosa rapidly traverse 
through the cribriform plate into the CNS  by 3 routes. 
1. Directly by the olfactory neurons. 
2. Through the supporting cells and the surrounding capillary bed  
3. Directly into the cerebrospinal fluid 
 Transneuronal absorption is generally slow, whereas absorption 
by the supporting cells and the capillary bed is rapid. 
 Intranasal midazolam has been successfully used in 
1. dental procedures  
2. endoscopic procedures 
3. cardiac catheterization 
4. accident and emergency cases 
5.  minor surgical procedures 
6. change of dressings and suturings 
7. febrile seizures 
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MIDAZOLAM NASAL SPRAY (INSED ATOMISER) 
 
 Insed Atomiser is a metered dose inhaler available for intranasal 
administration containing 50 metered doses of midazolam. Each 
metered dose of 100 μl of Insed Atomiser delivers 0.5 mg midazolam. 
Intranasal midazolam has been used for over a decade now for 
sedating children before anaesthesia, due to its unique property of a 
good premedicant because of its sedative and anxiolytic properties. 
Insed atomiser can be used instead of rectal and intravenous drugs for 
the emergency of seizures, both in and out of hospital. 
Intranasal administration of midazolam results in bio-availability 
of 50% to 83% when compared to the IV administration.  The variation 
in bioavailability  depends on the method of administration, with 
atomisation  demonstrating higher levels than dropper application.     
 Nasal midazolam has a faster onset of action and 1 to 3 times 
higher peak plasma levels than rectal and oral midazolam.  
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REVIEW OF LITERATURE 
        
1. J.-M.Malinovsky et al.,(17)(British Journal of Anaesthesia 1993) 
compared plasma concentrations of midazolam after nasal, rectal and 
intravenous administration in forty five children aged  two to nine years, 
weighing between ten and thirty kgs  who were undergoing minor 
urological surgery. Children were allocated randomly to receive 
midazolam 0.2 mg/kg by the nasal, rectal or intravenous route. Venous 
blood samples were obtained before and up to 360 minutes after 
administration of the drug. Plasma concentrations of midazolam were 
measured by gas chromatography and electron  detection. After nasal 
and rectal administration, midazolam Cmax was 182ng/ml within 12.6 
minutes, and 48 ng/ml within 12.1 minutes. Rectal administration 
resulted in smaller plasma concentrations.  In the nasal group, a plasma 
concentration of  midazolam 100 ng/ml occurred at about 6 minutes. 
After 45 minutes, the concentration curves after intravenous and nasal 
midazolam were similar.   
2. N.Griffifth, S.Howell and D.G.Mason(7) (British Journal of 
Anaesthesia 1998) Compared two methods of administering midazolam  
intranasally in 44 surgical day-care children allocated randomly to 
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receive midazolam 0.2 mg/kg as drops or midazolam 0.1 mg/kg from an 
intranasal device. Behaviour was recorded on a four-point scale by the 
parent, nurse and anaesthetist. They found that there was no significant 
difference in the method of administration and midazolam by either 
method was equally effective. 
3. Gustaf L.Jungman et al.,(8) (pediatrics Vol.105 Jan 2000) 
investigated whether intranasal  midazolam given before insertion of a 
needle in a subcutaneously  implanted central venous port could reduce 
anxiety, discomfort, pain and procedure problems. Forty-three children 
with cancer participated in this randomized, double-blind, placebo–
controlled crossover study in which nasal administration of midazolam 
spray, 0.2 mg/kg body weight, was compared with placebo. Children, 
parents and nurses completed a Visual Analog Scale questionnaire to 
evaluate efficacy. Parents and nurses reported reduced anxiety, 
discomfort and procedure problems for children in the midazolam group 
and would prefer the same medication at next procedure. They also 
reported pain reduction. 
4. H.AL-Rakaf et al., (9) (International Journal of Paediatric Dentistry 
2001) compared the effects of  three different doses of intra-nasal 
midazolam in the conscious sedation of young paediatric dental patients. 
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Thrity-eight uncooperative young children aged 2-5 years were 
randomly assigned to one of three groups. 
• Group A – Intranasal midazolam 0.3 mg/kg 
• Group B – Intranasal midazolam 0.4 mg/kg 
• Group C – Intranasal midazolam 0.5 mg/kg 
 There was rapid onset of sedation with the maximal effect 
between eight and fifteen minutes. This sedation effect lasted for twenty 
five to forty minutes in Group A and B and for sixty minutes in Group 
C. They concluded that all 3 doses of intranasal midazolam were 
effective in modifying the behaviour of the uncooperative child to 
accept dental treatment. 
5. Singh N; Pandey RK(24)  (Journal of clinical Paediatric Dentistry 
2002) evaluated the safety and efficacy of orally administered 
midazolam in children as a sedative agent and to compare it with two 
other older agents, triclofos and promethazine. The study was conducted 
on ninety children between three and nine years, requiring short dental 
procedures. The patients were randomized into three study groups on the 
basis of the drugs to be administered. 
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• Group I – Midazolam 
• Group II – Triclofos 
• Group III – Promethazine 
 After administration of drugs in each group, the effects were 
evaluated in terms of onset of action, sedative effect, ease of treatment 
completion, recovery time and postoperative  amnesia. Midazolam was 
found to be the best drug among the three to produce conscious sedation 
in children. 
6. Kogan, Alexander MD et.al.,(14) (Paediatric Anaesthesia, 
Oct.2002) studied the effects of four routes of administration on the 
efficacy of midazolam for premedication in 119 unpremedicated 
children between one and five years, scheduled for minor elective 
surgery. They were randomly assigned into one of four groups. 
• Group I –     Intranasal midazolam 0.3 mg/kg 
• Group II –    Oral midazolam 0.5 mg/kg 
• Group III –   Rectal midazolam 0.5 mg/kg 
• Group IV –   Sublingual midazolam 0.3 mg/kg. 
 A blinded observer assessed the children for sedation and 
anxiolysis every five minutes prior to surgery. Quality of mask 
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acceptance for induction, postanaesthesia care unit behaviour and 
parents’ satisfaction were evaluated. There were no significant 
differences in sedation and anxiety levels among the four groups. 
Average sedation and anxiolysis increased with time, achieving a 
maximum at 20 minutes in group I and at 30 minutes in groups II-IV. 
Mask acceptance was good for more than 75% of the children. They 
concluded that intranasal, oral, rectal and sublingual midazolam 
produces good levels of sedation and anxiolysis. Mask acceptance for 
inhalation induction was easy in the majority of children, irrespective of 
the route of drug administration. 
7. Charles J.Cote et al.,(3)(Anesth Analg 2002)examined the efficacy, 
safety and taste acceptability of three doses (0.25, 0.5 and 1.0 mg/kg 
upto a maximum of 20 mg) of commercially prepared versed syrup 
(midazolam Hcl) in children stratified by age (6 months to 2 yrs, 2 to < 
6 yr, and 6 to < 16 yrs.). There was no apparent relationship between 
dose and onset of sedation and anxiolysis. 88% had satisfactory anxiety 
ratings at the time of attempted separation from parents, and 86% had 
satisfactory anxiety ratings at face mask application. They concluded 
that oral midazolam syrup was effective for producing sedation and 
anxiolysis at a dose of 0.25 mg/kg with minimal effects on respiration 
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and oxygen saturation even when administered at doses as large as 1.0 
mg/kg as the sole sedating medication to healthy children. 
8. Christy Lam et al.,(4)(Anesth Prog 2005) compared the 
effectiveness of intramuscular and intranasal midazolam used as a 
premedication before intravenous conscious sedation. The study was 
conducted on twenty-three children from 2 to 9 years who were 
scheduled to receive dental treatment under intravenous sedation. 
  The sedation level, movement and crying were evaluated at the 
following time points: 10 minutes after drug administration and at the 
time of parental separation, nitrous oxide nasal hood placement, local 
anesthetic administration and initial venepuncture attempt. Intranasal 
midazolam was found to be as effective as intramuscularl midazolam in 
providing a better sedation level and less movement at the time of 
venepuncture. 
9. Asif Pervez Kazemi et.al.,(2)(Pakistan J Med Science 2005) 
compared the sedative effect of ketamine and midazolam administered 
nasally as premedication. 130 children aged two to five years were 
randomly allocated in three groups and 20 minutes before surgery 
received either 0.2 mg/kg midazolam or 5 mg/kg ketamine or 2 ml 
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normal saline, intranasally. At the time of separation and at the time of 
intravenous line insertion, they received a sadation score based on Sury 
and Cole sedation score. 
 According to statistical analysis, at the time of separation from 
parents 90% of patients were sedated in midazolam group,89% were 
sedated in ketamine group,  while in placebo group 47.5% showed 
sedation. At the time of intravenous line insertion, in midazolam group 
86% were sedated, in ketamine group 80% were sedated while in 
placebo group 22.5% showed sedation. They concluded that midazolam 
0.2 mg/kg and ketamine 5 mg/kg administered intranasally in children 
aged 2-5 years was equally effective for easier separation of children 
from their parents and obtunding their response to  venepuncture. 
10. Daniel P. Wermeling et al.,(5)(Anesthesia & Analgesia 2006) 
evaluated the  bioavailability of a novel intranasal midazolam 
formulation and compared the pharmacodynamic effects on  
psychomotor  performance and subjective reporting of drug effect after 
single  five mg doses of midazolam via  intranasal, intramuscular and 
intravenous routes of administration in twelve healthy volunteers. The 
intranasal formulation, a nonaqueous solution containing 25mg/ml 
provided 2.5 mg of midazolam in 0.1 ml spray from a  modified version 
of a commercially available unit-dose spray pump. Blood samples were 
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taken serially from 0 to 12 hr after each dose. Plasma midazolam 
concentrations were determined by liquid chromatography/mass 
spectrometry. The mean midazolam bioavailabilities and % coefficient 
of variation were 72.5 and 93.4 after the  intranasal and intramuscular 
doses respectively. They concluded that intranasal midazolam was a 
therapeutic alternative for aconvenient, noninvasive and rapidly acting 
sedative and the novel formulation  was rapidly and reliably absorbed. 
11. Parag Gharde, Sandeep Chauhan, Usha Kiran(22)(Annals of 
cardiac Anaesthesia 2006) compared the efficacy of intranasal 
midazolam, ketamine and their mixture as premedication in children 
with Tetrology of Fallot (TOF) undergoing intracardiac repair using 
bispectral index (BIS), sedation score and separation score at the time of 
separation from parent. Sedation score at the time of intravenous 
cannulation was also measured. Sixty children with TOF were randomly 
divided into three equal groups.   
 Group A – Intranasal Ketamine (10 mg/kg) 
 Group B – Intranasal midazolam (0.2 mg/kg) 
 Group C – Intranasal mixture of Ketamine (7.5 mg/kg) and 
midazolam (0.1 mg/kg) 
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 After thirty minutes of premedication, sedation and separation 
scores were noted. BIS values were recorded at 5 minute intervals. A  
four point scale for sedation, separation and acceptance of intravenous 
cannulation was used. They found out that sedation was good in 
midazolam group and concluded that the mixture of ketamine and 
midazolam intranasally was  better than  midazolam alone. 
12. Lee-Kim,S.J.S.Fadavi, et al.(16)(J  Dent child 2004) evaluated and 
compared intranasal and oral midazolam for effect on behaviour, time of 
onset, efficacy and safety for patients requiring dental care. Forty 
anxious subjects were sedated  randomly with either intranasal(0.3 
mg/kg) or oral(0.7mg/kg) midazolam. They concluded that mean onset 
time was approximately three times faster with intranasal administration 
compared to per oral administration. Overall behaviour under  oral and 
intranasal was similar. All vital signs were stable throughout the 
procedures with no significant differences between the two groups. 
13. Levent V.Karabas et al.,(29)(Journal of Paed Ophthal and 
Strabismus 2006,vol.43) investigated the effectiveness of topical 
anesthesia with sedation using intranasal midazolam in patients with 
symptomatic congenital nasolacrimal duct obstruction undergoing 
probing. 74 patients were divided into two groups, probing was 
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performed  with general anaesthesia in 30 cases and with  topical 
anesthesia using intranasal midazolam (0.3 mg/kg) in 44 cases. They 
concluded that probing under topical anaesthesia with intranasal 
midazolam was cost-effective, safe and comparable in efficacy to 
probing under general anaesthesia but with less risk. 
14. Shashikiran ND, Reddy Subba(21) (J Indian Soc Pedod Prev Dent 
2006)  evaluated midazolam  as a Paediatric conscious agent and 
compared its efficacy and  safety when  administered  by  intranasal and  
intramuscular routes, at a dosage of 0.2mg/kg body weight. These 
children were randomly assigned to two groups consisting of 20 subjects 
each. Group M received midazolam intramuscularly, while Group N 
received midazolam intranasally. Both the intranasal and intramuscular 
groups  showed  highly significant decrease in crying levels, motor  
movements and sensory perception levels. Though both the routes 
almost matched each other  in their efficacy and safety  profiles, the 
intranasal  route  showed a significantly  faster pharmacodynamic 
profile in terms of faster onset, peak and  recovery times. They 
concluded  that midazolam  could be  safely and successfully employed 
by  intranasal and intramuscular routes for Paediatric conscious sedation  
 26
in a  routine dental setup with  basic facilities at a dosage of 0.2 mg/kg 
body weight. 
15. PradiptaBhakta, B.R.Ghosh, Manjushree Roy(23)(Indian Journal of 
Anaesthesiology 2007) evaluated the efficacy of intranasal midazolam 
for preanaesthetic medication in paediatric patients. Forty five patients 
of two to five years of age belonging to ASA I and II, scheduled for 
minor elective surgery for this study. Patients were divided into three 
equal groups. 
• Group   I   -        Normal saline intranasally 
• Group   II    -     0.2 mg/kg  midazolam intranasally 
• Group  III   -     0.3 mg/kg  midazolam  intranasally 
 Vital parameters and level of sedation using a sedation scale were 
assessed before administering the drug and at five minutes intervals up 
to induction of  anaesthesia. A statistically significant change in the 
level of sedation was found at 5 minutes in group II and at ten minutes 
in group III compared to control group. Parental separation was easier in 
midazolam groups. Mask acceptance rate was found to be higher in 
midazolam groups. They concluded that intranasal midazolam in a dose 
of 0.2 mg/kg is an effective premedication for producing effective 
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sedation and anxiolysis in paediatric patients without any untoward side 
effect and no added advantage was found in 0.3 mg/kg dose. 
16. SunnyAlex, Barbara Coelho, Ambareesha M(25)(J Anaesth 
Clinical Pharmacology 2008) Compared the efficacy of nasal and oral 
midazolam as premedicant in preschool children. Sixty paediatric 
patients  in the age group of one to six years scheduled for elective 
surgeries were included in this study. The children were randomly 
allocated into two groups I and II 
• Group I   - Oral midazolam 0.5 mg/kg with oral 
atropine0.04 mg/kg 
• Group II - Nasal midazolam0.3 mg/kg with oral 
atropine0.04mg/kg 
The drug used orally was the injectable preparation 5 mg/ml 
ampoule. The drug was mixed with sugar to mask the bitter taste before 
administration. The same preparation was used nasally. The calculated 
dose was taken in syringe and half dose administered into each nostril. 
The children were evaluated for baseline anxiety, time of onset of action 
of drug, time of onset of action of drug , time for satisfactory sedation, 
levels of sedation on a five point score, levels of anxiety on a four point 
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score, co-operation at the time of mask application. The mean  time for 
onset of sedation and satisfactory sedation were 14.03 minutes and 18.3 
minutes respectively for the oral midazolam group and 8.63 and 11.3 
minutes for nasal midazolam group. 
They concluded that both oral and nasal midazolam were 
effective as premedicants in preschool children, oral tolerated better than 
nasal and onset of sedation and satisfactory sedation were faster for 
intranasal route. 
17. Lane, Roni D,  Schunk, Jeff  E (15)( J of  Pediatric emergency care, 
May 2008) performed a retrospective chart review of children who 
received intranasal midazolam sedation in the pediatric emergency 
department from April 1,2005 through June 30,2005. All children aged  
one to sixty months who received intranasal midazolam as the initial 
means of sedation were eligible for the study. A Mucosal Atomizer 
Device(MAD) was used to administer midazolam intranasally.The 
atomizer  was attached to an  one ml syringe and sprayed at a dose of 
0.4 mg/kg with a maximum of 10 mg while the child was sitting upright. 
Onset of sedation, degree of sedation, NPO status, additional 
medications given and adverse events were recorded. 
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 The majority of patients in this study achieved a level of mild to 
moderate sedation using atomized intranasal midazolam. Ninety-five 
percent of  children did  not require an additional sedative agent to 
complete the procedure. They concluded that atomized intranasal 
midazolam was effective in providing anxiolysis to children undergoing 
minor procedures in the paediatric emergency department. They also 
found that no adverse events occurred with the use of intranasal 
midazolam alone  despite relatively short fasting times. 
18. McCormick, A.S.M.,Thomas, V.L. Berry,D. (19) (British Journal 
of Anaesthesia 2008) compared two potential methods of administering 
midazolam by the nasal and nebulized routes. Midazolam (0.2 mg/kg) 
was given by both nebulizer and nasally by liquid instillation to ten 
healthy volunteers . Plasma concentrations of midazolam, Ramsay 
sedation score, visual analogue scores and parameters of cardiovascular 
and respiratory function were measured over 60 minutes. They found 
that  nasal instillation was associated with higher plasma concentrations 
and caused more sedation than nebulized administration. They 
concluded that a higher dose might be needed for adequate pre-
anaesthetic medication when midazolam was given by nebulizer.  
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MATERIALS AND METHODS 
 
     Seventy paediatric patients belonging to ASA physical status  
I and II scheduled for elective minor surgical procedures were included 
in the study.   
 Children belonged to age group of 2 to 8 years of both sexes. 
 The children were randomly allocated into 2 groups with  
35 patients in each group. (Group N and Group O). It was a comparative 
study.   
 The study was approved by the Institutional Ethical Committee 
and parents provided written informed consent before premedication of 
their children. 
Inclusion Criteria  
y ASA   I  and  II  physical status   
y Age group 2-8 yrs 
y weight  < 20 kgs 
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EXCLUSION CRITERIA 
y ASA III and IV 
y Nasal Infection 
y Nasal Pathology 
y Nasal Allergy and URI 
y Children with Seizure disorder 
y History of adverse reactions to benzodiazepines 
y patient taking other sedative drugs. 
MATERIALS 
• Nasal midazolam spray (Insed atomiser) 
• Oral midazolam 
PREPARATION OF THE PATIENT 
 Written informed consent from the parent obtained. 
 All patients fasted as per NPO guidelines.  
 Demographic data  including age, weight and sex of the children 
were  recorded. 
 The children were given premedication 30 minutes before surgery  
orally or nasally. The reaction of the  children to the premedication 
was noted. 
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y Group – N – received intranasal midazolam at a dose of 0.2mg/kg 
using  Insed atomiser midazolam Nasal spray containing 100 
micro litre / metered dose which delivers 0.5 mg/dose. The dose  
was calculated and divided equally into each nostril with the 
children in sitting position on their mothers’ lap. Half of the dose 
was placed in each nostril .Placing half the medication in each 
nostril reduced the volume while doubling the available area for 
absorption. Then the patient was kept in slightly head-down 
position for 2 minutes for easy absorption.  
Dosing guidelines of Nasal Spray 
Age (years) Approximate Wt Dose (mg) 
Metered Doses in 
each nostril 
1-2 6-8 1.2 – 1.5 1-2 
2-5 8-15 1.5 – 3.0 2-3 
5-10 15-30 7.5 – 10 6-8 
 
y Group – O – received oral midazolam at a dose of 0.5 mg/kg. The 
drug used was the injectable preparation which contains  
preservative free midazolam one ml (5mg/ml) in an ampoule.  
The drug was mixed with apple juice to mask the bitter taste 
before administration. 
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y After premedication, the children were observed carefully in the 
premedication room. Pulse oximeter was connected to the 
children and pulse rate and saturation were observed. 
y The onset of sedation, levels of sedation and anxiolysis at 10, 20 
and 30 minutes were noted. The reaction of the children  at the 
time of separation from parents were noted and graded as per the 
co-operation score. 
y After bringing the child to the theatre, an intravenous cannulation 
was done and child’s response to  venepuncture was noted and 
scored. 
y Standard Monitors such as ECG, Pulse Oximeter, Non-invasive 
BP, Precordial Stethescope were attached.  
y Anaesthesia was induced and response of the child to mask 
application was  noted and scored  before surgery was started. 
y The children were kept in the recovery position  after the surgery 
was over and observed in the operating room for 30 minutes and 
shifted to the recovery room.    
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OBSERVATIONS 
y Time of Onset of Sedation 
y Sedation Score at various points of time (10 minutes 
intervals for 30 minutes) 
y Anxiolysis score at various points of time (10 minutes 
intervals for 30 minutes) 
y Co-operation score at the time of separation from parents 
y Co-operation score at the time of mask application 
y Co-operation score at the time of venepuncture. 
 The presence or absence of the following side effects and 
complications from the time of instillation to 24 hours postoperatively, 
were noted. 
• Nasal irritation  
• Postoperative – nausea and vomiting  
• Respiratory depression  
• Laryngospasm/ Bronchospasm 
• Other complications  
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SEDATION SCORE 
Criteria Grade Score
Moving, physical or verbal  display 
of apprehension 
Alert /Active – agitated 1 
Tearful, clinging to mother Upset/ Worried 2 
Calm, responding readily to 
commands 
Relaxed 3 
Easily arousable Drowsy 4 
 
ANXIOLYSIS SCORE  
Criteria Grade Score
Afraid and crying, restrained  Poor 1 
Fearful, moderate apprehension  Fair  2 
Slightly fearful Good 3 
No fear or apprehension  Excellent  4 
 
CO-OPERATION SCORE  
Criteria Grade Score
Strongly refuses intervention  Poor 1 
Considerable effort required to 
achieve intervention  
Fair  2 
Accept intervention reluctantly Good 3 
Accept intervention readily Excellent  4 
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OBSERVATION AND RESULTS 
 
 The study was conducted in Paediatric Surgery operation theatres, 
New Paediatric block,  Government Stanley Medical college hospital. 
TYPES OF SURGERIES 
SURGERY GROUP N GROUP O TOTAL 
Herniotomy 7 10 17 
PV sac ligation 4 4 8 
Circumcision 17 10 27 
Others 7 11 18 
 
ASA GRADE 
 All patients of both groups belonged to ASA Grade I and II 
DEMOGRAPHIC  PROFILE 
 The sample of 70 was taken for study.  Test statistics used were 
Chi-Square test and ‘t’ test.                 
 The level of statistics significance was set up at p < 0.05%  
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TABLE-1 
Comparison of Age distribution  
Group N Mean (Years) S.D Std.Error mean 
Nasal 35 3.59 1.54 0.260 
Oral 35 3.80 1.38 0.233 
 
 Chi – Square value is 1.645, p value = 0.649 
 
 
Figure : Bar Diagram Compares the age  
distribution of Nasal and Oral group 
 
 The mean age in nasal midazolam group is 3.5 years and in oral 
midazolam group is 3.8 years. The data is statistically insignificant 
(p>0.05) and thus both groups are comparable in terms of age.  
N
um
be
r 
of
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as
es
  
Nasal  
Oral  
1= < 3 yrs  
2= 3- 4yrs 
3= 4-6yrs  
4= > 6yrs 
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TABLE-2 
Comparison of weight distribution 
GROUP N Mean (Kgs) S.D Std. Error mean 
Nasal 35 11.82 2.43 0.410 
Oral 35 12.17 2.46 0.417 
 
 Histogram of Weight – Nasal   Histogram of weight-Oral 
 
 
 
    
 
   WEIGHT (kgs)     WEIGHT(kgs) 
 
Figure : Histogram compares the weight distribution  
of Nasal and Oral group 
 The mean weight in Nasal group is 11.82 kg and in oral group is 
12.17 kg.  The data is statistically insignificant (p>0.05) and thus both 
groups are comparable in terms of weight. 
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TABLE - 3 
Comparison of Sex Distribution  
Group Female Male Total 
Nasal 5 30 35 
Oral 6 29 35 
Total  11 59 70 
 
0
5
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25
30
35
Nasal Oral
Female
Male
 
Figure : Bar Diagram shows Sex Distribution of   
Nasal and Oral group 
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TABLE-4 
Comparison of time of onset of sedation 
Group No MEAN (mts) S.D Std. Error mean 
Nasal 35 8.42 2.07 0.350 
Oral 35 15.82 2.73 0.462 
 
Independent Samples Test  
Time of onset of sedation 
 
 
Levene’s Test 
of Variances T-test for Equally of Means 
F Sig. T df Sig. (2-tailed)
Mean 
Difference
Std. Error 
difference 
95% Confidence 
Interval of the 
difference
Lower Upper
Equal variances 
assumed  
Equal variances 
not assumed 
2.578 .113 -12.739
 
-12.739
68 
 
63.381
.000 
 
.000 
-7.4000 
 
-7.4000 
.58089 
 
.58089 
-8.559 
 
-8.556 
 
-6.240
 
-6.239
  
 
 
 
 
Figure : Hisogram compares the time of onset of  
sedation in Nasal and Oral groups 
 The mean time of onset of sedation in nasal midazolam group  is  
8.42 minutes and in oral midazolam group is 15.82 minutes. The data is 
statistically  highly significant (p= 0.000).  
0.0
2.5
5.0
7.5
10.0
4.0 6.0 8.0 10.0 12.0
Histogram of Time of onset of sedation-Nasal
Time of onset of sedation.
N
o.
 o
f C
as
es
 
0.0
3.5
7.0
10.5
14.0
12.0 14.5 17.0 19.5 22.
0
Histogram of Time of onset of sedation Oral
Time of onset of sedation. 
N
o.
 o
f C
as
es
 
 41
TABLE -5 
Sedation Score at 10 Minutes  
Cross table
  GROUP  
   Nasal Oral Total 
Sedation Score 
10 Minutes 
1.00 Count 0 30 30 
% within Group .0% 85.7% 42.9% 
2.00 Count 18 5 23 
% within Group 51.4% 14.3% 32.9% 
3.00 Count 16 0 16 
% within Group 45.7% .0% 22.9% 
4.00 Count 1 0 1 
% within Group 2.9% .0% 1.4% 
 Total Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
Chi – Square value is 54.348, P value = 0.000 
 
  
 
 
 
 
 
Figure : Bar diagram Compares Sedation score at  
10 minutes in Nasal and Oral Groups    
 The sedation score in 10 minutes is statistically significant 
with a  P value of  0.000<0.05 
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TABLE -6 
Sedation Score at 20 Minutes 
Cross table
   GROUP  
   NASAL ORAL Total 
Sedation Score 
 20 Minutes 
1.00 Count 0 4 4 
% within Group .0% 11.4% 5.7% 
2.00 Count 0 15 15 
% within Group .0% 42.9% 21.4% 
3.00 Count 26 14 40 
% within Group 74.3% 40.0% 57.1% 
4.00 Count 9 2 11 
% within Group 25.7% 5.7% 15.7% 
 Total Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
Chi – Square value is 27.055, P value = 0.000 
 
 
 
 
 
 
 
 
 
Figure : Bar diagram Compares Sedation score at  
20 minutes in Nasal and Oral Groups    
  The Sedation score in 20 minutes is highly statistically 
significant with a P value < 0.05 
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TABLE -7 
Sedation Score at 30 Minutes  
Cross table
  GROUP  
   Nasal Oral Total 
Sedation Score 
30 Minutes 
2.00 Count 0 1 1 
% within Group .0% 2.9% 1.4% 
3.00 Count 7 20 27 
% within Group 20.0% 57.1% 38.6% 
4.00 Count 28 14 42 
% within Group 80.0% 40.0% 60.0% 
 Total Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
Chi – Square value is 11.926, P value = 0.003 
 
 
 
 
 
 
 
Figure : Bar diagram Compares Sedation score at  
30 minutes in Nasal and Oral Groups 
 Sedation score in 30 minutes is statistically significant with a       
P value of 0.003 < 0.05 
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TABLE -8 
Anxiolysis  at 10 Minutes  
Cross table 
Anxiolysis 
10 Minutes 
GROUP  
Nasal Oral Total 
1.00 Count 0 6 6 
% within Group .0% 17.1% 8.6% 
2.00 Count 13 17 30 
% within Group 37.1% 48.6% 42.9% 
3.00 Count 20 9 29 
% within Group 57.1% 25.7% 41.4% 
4.00 Count 2 3 5 
% within Group 5.7% 8.6% 7.1% 
Total Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
 Chi – Square value is 10.906, P value = 0.012 
 
 
 
 
 
 
 
Figure : Bar diagram Compares Anxiolysis at  
10 minutes in Nasal and Oral Groups 
 
 Anxiolysis score in 10 minutes is statistically significant with a 
P value of 0.012<0.05. 
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TABLE - 9 
Anxiolysis  at 20 Minutes  
Cross table 
Anxiolysis 
20 Minutes 
GROUP  
Nasal Oral Total 
2.00 Count 1 4 5 
% within Group 2.9% 11.4% 7.1% 
3.00 Count 23 18 41 
% within Group 65.7% 51.4% 58.6% 
4.00 Count 11 13 24 
% within Group 31.4% 37.1% 34.3% 
Total Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
 
 
 
 
 
 
 
Figure : Bar diagram Compares Anxiolysis at  
20 minutes in Nasal and Oral Groups 
 P value is 0.276 
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TABLE - 10 
Anxiolysis at 30 Minutes  
Cross table 
Anxiolysis 
30 minutes 
GROUP  
Nasal Oral Total 
3.00 Count 6 15 21 
% within Group 17.1% 42.9% 30.0% 
4.00 Count 29 20 49 
% within Group 82.9% 57.1% 70.0% 
Total Count 35 35 70 
% within GROUP 100.0% 100.0% 100.0% 
 
 Chi – Square value is 5.510, P value = 0.019 
 
 
 
 
 
 
 
Figure : Bar diagram Compares Anxiolysis at  
30 minutes in Nasal and Oral Groups 
Anxiolysis in 30 minutes is statistically significant with a P value of 
0.019(<0.05) 
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TABLE - 11 
CO-OPERATION SCORE-PARENTAL SEPARATION  
Cross table 
Co-Operation Score-
Parental Separation 
GROUP  
Nasal Oral Total 
2.00 Count 2 4 6 
% within Group 5.7% 11.4% 8.6% 
3.00 Count 25 17 42 
% within Group 71.4% 48.6% 60.0% 
4.00 Count 8 14 22 
% within Group 22.9% 40.0% 31.4% 
Total Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
 Chi – Square value is 3.827, P value = 0.148 
 
 
 
 
 
 
 
Figure : Bar diagram Compares co-operation score for  
parental separation in Nasal and Oral Groups 
The data is statistically not significant as the P value is 0.148(>0.05)  
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TABLE - 12 
CO-OPERATION SCORE - VENE PUNCTURE  
Cross table 
VENE PUNCTURE GROUP  Nasal Oral Total 
2.00 Count 0 3 3 
% within Group .0% 8.6% 4.3% 
3.00 Count 17 20 37 
% within Group 48.6% 57.1% 52.9% 
4.00 Count 18 12 30 
% within Group 51.4% 34.3% 42.9% 
Tota
l 
Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
 Chi – Square value is 4.443, P value = 0.108 
 
 
Figure : Bar diagram Compares co-operation score for  
Venepuncture in Nasal and Oral Groups 
The data is statistically not significant as the P value is 0.108( >0.05) 
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TABLE - 13 
CO-OPERATION SCORE FOR MASK APPLICATION 
Cross table
MASK APPLICATION GROUP  Nasal Oral Total 
3.00 Count 12 10 22 
% within Group 34.3% 28.6% 31.4% 
4.00 Count 23 25 48 
% within Group 65.7% 71.4% 68.6% 
Tota
l 
Count 35 35 70 
% within Group 100.0% 100.0% 100.0% 
 
 Chi – Square value is 0.256, P value = 0.607 
 
 
 
 
 
 
 
Figure : Bar diagram Compares co-operation score for  
Mask Application in Nasal and Oral Groups 
The data is statistically not significant as the P value is 0.607 ( >0.05) 
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DISCUSSION 
 
 Wilton NCT(27), Karl HW(12) and many others have searched for 
the ideal paediatric premedicating agent and also for the best route of 
administration. A paediatric premedicant must have an acceptable, 
atraumatic route of administration in addition to other characteristics 
needed for such a drug. 
 Midazolam has been extensively used in anaesthetic practice 
since 1982, and its pharmacodynamics and pharmacokinetics are well 
known. Midazolam is used frequently for premedication in children, 
preferably by non-parenteral routes. 
 Nasal administration of various drugs such as ketamine and 
midazolam has been recommended  previously for  premedication in 
children.  Oral midazolam  remains the commonly used premedication 
in paediatric outpatients. 
 Intranasal midazolam for premedication  in preschool children 
was  first described and advocated by Wilton and colleagues(27). 
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 Midazolam has many desirable properties as a premedicant in 
children undergoing surgery. Midazolam exerts a reliable dose 
dependent anxiolytic effect without oversedation and provides minimal 
cardiovascular and respiratory effects.  The anterograde amnesia 
produced by midazolam help reduce the psychological trauma of 
anaesthesia and surgery. Its elimination half life is 1.5 -2 hrs which is 
considerably shorter than that of diazepam. The elimination half life of 
intranasal midazolam is similar to that when the drug is given 
intravenously and no significant complications have been reported when 
it is given by the intranasal route. 
 As midazolam has many of the properties of an ideal permedicant 
drug, this comparative study was undertaken to compare the efficacy of 
this drug when given by oral and intranasal routes. 
  Most studies have used midazolam in a dosage of 0.1 to 0.3 
mg/kg intranasally and several pharmacokinetic studies have examined 
plasma concentrations and effect at varying intranasal doses. 
 Intranasal midazolam has generally been administered in the form 
of drops, which in the awake patient are difficult to keep in the nose and 
may be swallowed and subjected to first pass metabolism in the liver. 
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 Twersky and colleagues used a Devilbiss 286 atomizer to deliver 
0.2 mg/kg. Bjorkman, Rigemar and Idvall(30) used a spray bottle in 
adults   and found the procedure acceptable. Midazolam has also been 
given to adults  by nebulizer with good acceptability.  
 It has been shown that the fine aerosol would allow greater 
contact with the absorbing surface and that application  would be less 
unpleasant than drops. Bio-availability with nasal spray has been shown 
to be high (83%) with virtually complete absorption. 
 N. Griffifth et al., (7)compared two methods of administering 
midazolam intranasally in 44 day-care children and used midazolam 0.2 
mg/kg as drops or midazolam 0.1 mg/kg  from an intranasal  spray 
device. 
 Behaviour was recorded on a four point scale  and co-efficients 
were obtained representing the change in behaviour score. There was no 
significant  difference in the method  of administration (coefficient 0.13, 
p=0.39).  midazolam  by either method was  equally effective but 
acceptability of the premedication was poor in nasal drops group. 
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 Intranasal midazolam in the form of a spray was  used in this 
study. Each metered dose of 100  microliter of atomiser delivered 0.5 
mg of midazolam.    
 Oral midazolam  used in this study was the preservative free 
injectable    preparation (5  mg/ml ) in an ampoule. The  drug was mixed 
with the apple juice to mask the bitter taste and to increase the 
acceptability. 
 Sunny Alex et al., (25) used intranasal midazolam at a dose of  0.3 
mg/kg and oral midazolam in a dose  of 0.5 mg/kg in their study.   
 Charles J.Cote et al.,(3)studied 306 patients, using 3 different 
doses of oral midazolam  syrup 0.25, 0.5,1.0 mg/kg. Overall 97% of 
patients achieved satisfactory  sedation (score>3) after treatment. The 
difference between the 0.25 and 0.1 mg/kg  dosage was 
significant.(p<0.01). 
            There was no difference  between  the 0.5 and 1.0 mg/kg groups  
or between the 0.5 and 0.25 mg/kg groups. After  study medication,  
99% maintained satisfactory sedation scores and 97.5% achieved   a 
satisfactory anxiolytic response(score>3). There  was a  positive 
association  between  dose and onset of anxiolysis(p=0.01); a larger 
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proportion of children achieved satisfactory anxiolysis within 10 
minutes at  the higher doses. >90% maintained satisfactory anxiolysis 
for upto 45 minutes. 
 No child experienced respiratory complications before induction, 
two experienced nausea and three vomited before induction. The 
proportion of subjects experiencing an adverse event was slightly larger 
in the 1.0 mg/kg. 
 Hence it was decided to use oral midazolam in a dose of 0.5 
mg/kg for all children in the oral group in this study  and none of them 
experienced  respiratory depression, nausea, vomiting or any adverse 
effect. 
 Asif Pervez et al.,(2)compared the effect  of  intranasal midazolam  
with   intranasal ketamine and used intranasal midazolam in a dose of 
0.2 mg/kg. 
 In a study performed by Garcia-Velasco P et al.,(28) intranasal 
midazolam was used in a dose of 0.25 mg/kg and it compared it with 
ketamine (5mg/kg) nasally and found that the nasal route of 
administration of the drug was well accepted in both groups and 
midazolam and Ketamine were equally effective as sedative 
premedication. 
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       Gustaf L jungman et al.,(8)conducted a double blind, placebo 
controlled, crossover study in which nasal administration of midazolam   
spray 0.2 mg/kg  was compared with placebo. 
 Sunny Alex et al.,(25)used a five point score for level of sedation, 
four point score for level of anxiety and a four point score for co-
operation at the time of parental separation. 
 Sedation score at 10, 20, 30, 40  minutes and at the time of 
separation from parents were evaluated and compared between the oral 
and nasal midazolam groups. 
 In our study, mean time for onset of sedation, time for satisfactory 
sedation, level of sedation at 10 minutes, 20 minutes, and 30 minutes, 
level of anxiety at 10 minutes, 20 minutes, 30 minutes in both the 
groups were compared. In addition, co-operation at the time of 
separation from parents, co-operation at the time of venepuncture and 
co-operation at the time of  mask application were scored and compared. 
 A four point scale for sedation score, five point scale for 
anxiolysis score and a four point scale for co-operation score were used 
to compare the groups in this study. 
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 In our study, the mean time for onset of sedation in nasal 
midazolam group was found to be 8.42 minutes and in oral group it was 
15.8  minutes. Thus the onset time in oral group was almost twice that 
of nasal group. 
 Sunny Alex et al.,(25) found that the mean time for onset of 
sedation and satisfactory sedation were 8.63 minutes and 11.3 minutes 
respectively for the nasal midazolam group and  and 14.03 minutes and 
18.3 minutes for the oral midazolam group with P value of 0.001 which 
was very highly significant.   
 Christy Lam et al.,(4)compared the effectiveness of intramuscular 
and intranasal midazlolam as a premedication before intravenous 
conscious sedation. The patients ranged in age from 2-9 yrs ( mean age 
5.13 yrs) and received  a dose of 0.2 mg/kg of midazolam  via 
intramuscular or intranasal administration. They studied 23 patients and  
reported that  patients who were given intramuscular midazolam were 
more deeply sedated than those receiving intranasal midazolam.  
 Karl HW et al., (12)  showed that the rich blood supply of the nasal 
mucosa allows rapid absorption of drugs directly into the systemic 
circulation. Absorption depends on the time that the drus is adjacent to 
the mucosal surface (Resident time), local pH (6-7), presence of 
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secretions (respiratory tract infections), physicochemical properties of 
the drug  and physicochemical properties of  route of the administration 
of the drug. 
 The  method and technique of administration also affect the drug 
absorption. The aqueous solubility of midazolam at acidic pH (3.5)  
allows this drug to maintain a high concentration in nasal mucosa  
(pH 6-7). The   pKa of  midazolam 6.15 which  is  close to local pH. 
Both ionized and nonionized forms are absorbed from nasal mucosa. 
 Kogan et al.,(14) studied the effects of oral, rectal and nasal 
midazolam. The children accepted oral route  significantly better 
compared to nasal or oral routes. The fastest onset of sedation was found  
after rectal route. The  effect of oral midazolam was good in many 
children but less predictable. 
 Asif Pervez et al.,(2) conducted  the study on paediatric surgical 
patients in 2-5 yr age group. Our study was conducted on patients 
between 2-6 yrs.  
 In the study conducted by Sunny Alex et al.,(25)sedation scores 
were slightly better in the nasal group upto 20 minutes after 
premedication with P value of 0.006 which was highly significant at 10 
minutes, and P value of 0.028 which was significant at 20 minutes. At 
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30 minutes , 40 minutes and at the time of separation from parents 
sedation scores were comparable between two groups with p value of 
>0.05 which was statistically insignificant. 
 In our study, statistical analysis showed that sedation score at 10 
minutes was better with the nasal group  with a P value of <0.001 which 
is statistically highly significant. 
 Sedation score at 20 minutes after premedication was better with 
nasal midazolam with a P value of < 0.001 which is again statictically 
significant. Sedation score at 30 minutes was better in the nasal group  
with a P value of 0.003  which is statistically significant. 
 In our study, anxiolysis scores were better with the nasal group  
with p value of  0.012 at ten minutes and twenty minutes and a P value 
of 0.019 at thirty minutes which are statistically significant. But this 
contradicts the study of Sunny Alex et al.,(25) who found the anxiolysis 
score to be similar in the two groups (nasal and oral) throughout the 
study period  with a p value of  >0.05 which was not significant 
statistically. 
 In our study, co-operation scores at the time of parental separation 
are comparable in both groups with a P value of 0.148 which is 
 59
statistically  not significant. This result can be correlated with the study 
of Sunny Alex et al., who had similar results. 
 Co-operation scores at the time of venepuncture are  found to be 
similar in both groups with a P value of 0.108 which is not statistically 
significant. This also correlates with the study of Sunny Alex et al.,(25) 
who had the same results. 
 The co-operation for mask application is comparable in both 
groups with a P value of > 0.05 which is not statistically significant. 
 In both groups no patient had coughing, gagging, vomiting, 
laryngospasm  or respiratory depression.   
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SUMMARY 
 
 We compared the efficacy of midazolam as a paediatric 
premedication when used in two different routes. 
 Midazolam was used as premedication  in intranasal and oral 
routes in children undergoing minor surgical procedures and the efficacy 
of the drug  in producing preoperative sedation, anxiolysis and co-
operation during separation from the parents, venepuncture and face 
mask application  was compared using  separate scoring systems. 
 The following observations were made during the study. 
 There are no significant differences  between the two groups in 
demographic data. 
 The time of onset of sedation is 8.42 minutes with intranasal 
midazolam and 15.82 minutes with oral midazolam. 
 We observed that  intranasal midazolam has more rapid onset of 
action  compared to oral midazolam, which is statistically significant. 
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 The sedation scores are better with intranasal midazolam than oral 
midazolam at 10 minutes, 20 minutes and30 minutes  which are 
statistically significant. 
 The anxiolysis is better with nasal midazolam group with 
statistical significance. 
 There is no significant  difference in the co-operation score for 
venepuncture, separation from the parents and mask application between 
the two groups. 
 No patient was oversedated or drowsy postoperatively. No 
complications were observed in both the groups. 
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CONCLUSION 
 
 In conclusion, Intranasal midazolam when used as a 
premedication in children, in   a dose of 0.2 mg/kg has more rapid onset 
of action with satisfactory sedation and anxiolysis than oral midazolam. 
The rapid onset of action of nasal midazolam makes it an ideal route for 
premedication in children. 
 PROFORMA 
 
Name    : 
Age    : 
Sex    : 
Weight   : 
IP No.    
ASA Physical Status : 
Diagnosis   : 
Procedure   : 
Duration of Surgery : 
Baseline Anxiety  : 
 
 
Oral Nasal 
  
 
 
I. Time of onset of sedation (minutes)   :  
 
II. Sedation score at various points of time 
 
 
 
Time Group N Group O 
10 Minutes   
20 Minutes   
30 Minutes   
 
IV. Anxiolysis score at various points of time : 
Time Group N Group O 
10 Minutes   
20 Minutes   
30 Minutes   
 
V.        Co-operation score: 
 
Time Group N Group O 
Parental Separation   
Venepuncture   
Mask Application   
 
VI.      Complications if any : 
Respiratory depression, Salivation, Laryngospasm, Others 
 
 SEDATION SCORE 
Criteria Grade Score
Moving, physical or verbal  display 
of apprehension 
Alert /Active – agitated 1 
Tearful, clinging to mother Upset/ Worried 2 
Calm, responding readily to 
commands 
Relaxed 3 
Easily arousable Drowsy 4 
 
ANXIOLYSIS SCORE  
Criteria Grade Score
Afraid and crying, restrained  Poor 1 
Fearful, moderate apprehension  Fair  2 
Slightly fearful Good 3 
No fear or apprehension  Excellent  4 
 
CO-OPERATION SCORE  
Criteria Grade Score
Strongly refuses intervention  Poor 1 
Considerable effort required to 
achieve intervention  
Fair  2 
Accept intervention reluctantly Good 3 
Accept intervention readily Excellent  4 
 Sno Name  IP no Age (yrs)  Sex 
Wt 
(kgs) 
  Time of 
onset of 
sedation 
(mts) 
Sedation score Anxiolysis Co-operation score 
Compications Surgery 10 mins 20 mins 30 mins 10 mins 20 mins 30 mins Parental seperation 
vene 
puncture
Mask 
application 
1 Hariharan 060966 2 M 8 circumcision 5 2 3 4 2 3 4 3 4 4  
2 Gowtham 060958 2.5 M 10 circumcision 8 3 3 4 2 3 3 3 3 4  
3 Henry 060957 4 M 14 hypospacdias repair 6 3 3 4 2 4 4 3 4 4  
4 Kalaivani 060915 6 F 16 preauricularsinusexcision 5 3 3 4 3 3 4 3 3 4  
5 Jennifer 060771 4 F 14 tongue tie release 5 4 3 4 2 3 4 4 4 3  
6 Roshan 060869 2 1/2 M 10 circumcision 6 2 3 3 2 3 3 3 3 4  
7 Monesh 060870 2 M 10 circumcision 10 2 3 4 2 3 4 3 4 4  
8 Sachin 060871 7 M 16 rt.pvsacligation 8 2 4 4 3 3 4 3 4 4  
9 Santhosh 060614 2 M 8 circumcision 6 3 3 4 2 2 4 3 3 4  
10 Iyyapan 060618 2 1/2 M 9 circumcision 9 2 3 4 2 3 4 3 4 4  
11 Manohar 060617 3 1/2 M 12 circumcision 10 3 3 4 3 3 4 3 3 4  
12 Kumaran 060615 2 1/2 M 11 circumcision 10 2 3 3 2 3 4 3 3 4  
13 Saravanan 067613 4 M 12 circumcision 8 3 3 4 3 4 4 4 4 4  
14 Mahalaxmi 060742 3 1/2 F 12 rt.herniotomy 10 2 3 3 2 3 4 3 3 3  
15 Manivannan 060743 6 M 14 circumcision 9 2 4 4 3 4 4 3 4 4  
16 Ravi 60684 5 M 14 circumcision 10 3 3 4 3 3 4 4 4 3  
17 Kishore 60696 2 1/4 M 10 circumcision 8 2 3 4 3 4 4 4 3 4  
18 Karthikeyan 60700 3 1/2 M 13 circumcision 12 3 4 4 3 3 4 4 4 4  
19 Gowtham 60777 2 M 10 circumcision 10 2 3 3 3 3 4 3 3 3  
20 Saravana Kumar 60768 2 M 10 circumcision 12 2 3 3 2 3 3 3 4 3  
21 Rithish 66774 2 1/2 M 14 rt.pvsacligation 8 3 3 4 3 3 4 4 3 4  
22 Saikanth 60770 6 M 16 rt.pvsacligation 10 3 3 4 2 3 4 3 4 3  
23 Sira 62298 5 M 13 umblical h repair 9 2 3 3 2 3 3 3 4 3  
24 Bhuvanesh 62301 2 M 10 orchidopexy 9 2 4 4 3 4 4 4 3 3  
25 Hemesh Kumar 62306 3 M 9 herniotomy 10 3 3 4 3 4 4 3 4 4  
26 Susainathan 62229 2 1/2 M 10 circumcision 12 2 3 3 3 3 3 2 3 3  
27 Akash 62305 2 1/2 M 12 herniotomy 8 3 4 4 4 4 4 3 4 4  
28 Dhinakaran 62303 3 M 10 circumcision 6 3 4 4 3 4 4 2 4 4  
29 Hemanth 63289 3 M 10 tongue tie release 8 3 3 4 3 4 4 3 3 3  
30 Priyan 63282 2 1/2 M 10 rt.pvsacligation 6 3 4 4 3 3 4 3 3 4  
31 Vishwa 68288 7 M 15 l.herniotomy 12 2 3 4 3 3 3 3 4 4  
32 Manickam 63322 3 M 9 r.herniotomy 6 3 4 4 3 3 4 4 3 3  
33 Keerti 63319 5 F 15 tongue tie release 8 2 3 4 3 3 4 3 3 4  
34 Naveen 62353 4 M 13 herniotomy 7 2 3 4 3 4 4 3 3 3  
35 Pavithra  62352 6 F 15 herniotomy 9 2 4 4 4 4 4 3 4 4  
  
GROUP 'O'  
Sno Name  IP no Age  
(yrs) 
Sex Wt 
(kgs) 
 Surgery Time of onset of 
sedation 
(mts) 
Sedation score Anxiolysis Co-operation score Compications
10 mins 20 mins 30 mins 10 mins 20 mins 30 mins Parental 
seperation 
vene 
puncture 
Mask 
application 
1 Shadik 62243 2 1/2 M 13 prominent coccyx excison 15 1 3 4 1 4 4 3 3 3  
2 Sasi 62355 2 1/2 M 10 circumcision 18 1 2 3 1 3 3 3 4 4  
3 vignesh 62351 3    M 10 circumcision 20 1 1 3 1 3 3 3 4 4  
4 alisha 62356 5    M 12 circumcision 15 1 2 3 1 2 3 4 4 4  
5 Sarath babu 60495 2    M 10 r.herniotomy 12 2 3 3 1 3 3 3 3 4  
6 Vennila 60660 6    F 14 r.herniotomy 15 2 2 3 2 3 3 3 4 4  
7 Renuka devi 60655 5    F 12 mucus cystlip excision 13 1 1 2 1 3 3 4 4 4  
8 Mahadevan 60653 2    M 10 circumcision 12 1 2 3 2 4 4 4 3 4  
9 Vetrivel 60652 5    M 15 circumcision 16 1 2 3 2 4 4 4 3 4  
10 Muthuvel 60682 6    M 16 r.pvsl 18 1 4 4 2 4 4 4 4 4  
11 Mariam Sihana 63543 7    F 16 elective appendicecpomy 14 1 2 4 2 2 4 4 3 4  
12 Ajith 63522 6    M 15 elective appendicecpomy 12 1 1 4 2 3 4 4 3 4  
13 Yuvendran 63582 2 1/2 M 9 l.orchidopexy 15 1 2 4 2 4 4 3 3 3  
14 Yuvan 63584 2 1/2 M 10 r.pvsl 13 1 3 3 2 3 3 3 4 4  
15 Hemanth 63587 3 1/2 M 12 r.pvsl 15 1 3 4 2 3 3 4 3 4  
16 Madesh 63586 2 1/2 M 10 r.herniotomy 13 1 4 4 2 4 4 4 3 4  
17 Vinoth kumar 63581 3    M 11 r.herniotomy 12 2 2 3 3 4 4 3 4 4  
18 Niranjan 63583 2 1/2 M 10 circumcision 15 2 3 4 3 4 4 3 3 4  
19 Prashanth 63483 4    M 12 r.herniotomy 13 2 3 4 3 3 3 3 3 4  
20 Lenin 63580 4    M 14 r.herniotomy 12 1 3 3 2 3 3 3 3 3  
21 Anandhi 62865 5    F 15 sub mandibular sinus excison 18 1 2 3 3 4 4 3 4 4  
22 Puviarasu 63287 6    M 15 orchidectomy 20 1 3 4 3 3 4 4 4 4  
23 Mohammed 63286 5    M 13 r.pvsl 16 1 3 3 4 4 4 4 4 4  
24 Yathish 63283 3    M 10 r.herniotomy 15 1 3 3 4 4 4 3 3 4  
25 Vignesh 63299 3    M 12 tongue tie release 20 1 2 3 3 4 4 4 3 4  
26 Sanjay 64201 4    M 13 elective appendicecpomy 18 1 3 4 3 3 4 4 4 4  
27 Adhilaxmi 64238 5    F 15 demoid excision 18 1 2 4 4 4 4 3 3 4  
28 Jeeva 64234 2 1/2 M 8 r.herniotomy 16 1 2 3 3 3 4 3 3 3  
29 Monisha 64241 2    F 6 r.herniotomy 22 1 1 3 3 3 3 3 2 3  
30 Naveen 64240 4    M 15 tongue tie release 18 1 3 3 2 3 3 3 2 3  
31 Vijayakumar 64248 3    M 12 circumcision 16 1 3 4 2 3 4 4 3 4  
32 Chanakya 64247 3 1/2 M 12 circumcision 18 1 2 3 2 2 3 2 3 3  
33 Pradheen 64243 2 1/2 M 10 circumcision 16 1 2 4 2 3 4 2 3 3  
34 Praveen 64244 4    M 14 circumcision 20 1 2 3 2 2 3 2 3 3  
35 Vikram 63323 4    M 15 r.orchidectomy 15 1 3 3 2 3 3 2 2 3  
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INFORMED CONSENT FORM  
 
   I Mr./Mrs.__________ was informed by Dr. _________ 
that it was important to make my child calm and quiet before shifting 
him / her into the operating theatre for surgery. I was told that it was 
easier to make my child asleep by instilling the drug in the form of 2 -3 
nasal drops than by giving injection. 
 
 I clearly understand that this method is painfree and without side 
effects. As my child is not allergic to any drug, I willingly give my 
consent to make my child asleep by this method. 
 
 
Signature of the Parent 
 
 
 
 
 
 
 
The picture shows the child being premedicated  
with nasal midazolam spray 
 
 
Structure and Metabolism of midazolam 
 
 
 
 
 
Reversible ring opening of midazolam above and below a pH of 4 
 
 
 
 
 
 
 
Anatomy of the nasal mucosa-cribriform plate interface  
 
 
 
 
 
 
 
 
 
 
Lateral wall of the left Nasal Cavity showing the Olfactory Nerves 
 
 
 
 
 
Nasal midazolam spray 
 
 
  
 
  
 
 
This pictures shows the child at induction  
